Jianke Health Partners Conference in Chengdu: Empowering Industry Collaborators with Comprehensive Digital Intelligence Solutions

On August 8, the second stop of Fangzhou Pharmaceutical’s (06086.HK) Partner Conference was successfully held in Chengdu. More than 60 guests attended the event to witness this “Health Engagement” that brought together collective strength. At the conference, participants shared their insights and perspectives on “The Path of Transformation for Internet Healthcare and Traditional Pharmaceutical Companies Amidst the Digital Wave,” showcasing the current state of development in the healthcare industry from diverse viewpoints.

Entering 2024, the Chinese government has repeatedly issued policy documents emphasizing the strengthening of chronic disease management and prioritizing the development of internet-based healthcare. Meanwhile, many regions across China are progressively enabling online payment channels for medical insurance funds, making the prospects for “Internet + Chronic Disease Services” highly promising.

“Fangzhou Pharmaceutical is an enterprise that prioritizes technological research and development. In the face of the digital wave, we must accelerate our pace to seize critical opportunities for growth.” At the conference, Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, delivered a keynote address centered on topics such as “Digital Layout for Chronic Disease Management Services” and “Leading Internet+ Health Management.”

Caption: Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, delivers a keynote presentation.

From Traditional to Digital: It Is No Easy Feat for Enterprises to Upgrade Their Products and Services. How Can They “Run Faster” During Critical Periods? Xie Fangmin Believes That Focusing on Product R&D, Embracing Advanced Technologies, and Strengthening Collaboration and Exchange Are Crucial.

According to Xie Fangmin, the internet-based smart medical services currently developed by Fangzhou Pharmaceutical have completed the development and application in various business scenarios, including intelligent visual robots, intelligent text robots, and intelligent auxiliary management, thereby delivering more professional and compassionate services. Meanwhile, Fangzhou Pharmaceutical has created a precise digital marketing model for its partners, enhancing their product conversion rates and sales efficiency, and truly achieving “quality growth.”

Digital transformation is a significant and far-reaching endeavor. Xie Fangmin hopes that, in the future, Fangzhou Pharmaceutical will inject new quality productive forces into China’s healthcare sector, comprehensively empower partners through digital means, and work together to achieve high-quality development.

Driven by multiple factors, including advancements in digital marketing technologies and shifts in the market environment, the pharmaceutical industry’s digital marketing sector is entering a period of robust growth. Data indicates that the market size for pharmaceutical digital marketing is projected to expand further, reaching RMB 111 billion in 2025 and RMB 356.8 billion in 2030.

“Faster,” “Broader,” and “More Precise” will be the core hallmarks of future digital marketing, and collaboration between traditional pharmaceutical companies and internet hospitals is an irreversible trend. How can their partnership models be expanded into broader domains? What are the advantages of such collaborations following digital transformation?

At the conference, guests from Sichuan Credit Pharmaceutical Co., Ltd., Bayer Healthcare, Kelun Pharmaceutical, and Kanghong Pharmaceutical shared their insights, prompting deeper reflections among attendees on digital marketing.

Chen Gang, Chairman and General Manager of Sichuan Credible Pharmaceuticals Co., Ltd., stated that through patient-doctor education and brand marketing campaigns on the Fangzhou Pharmaceutical platform, the company can unlock product value and reach users in the out-of-hospital market. He expressed his expectation that both parties will join hands to explore a new “pharmaceutical industry + internet healthcare” model and set an industry benchmark.

“Diversified women’s health business: Precise service experience is key.” Yuan Junjie, General Manager of Bayer’s Prescription Drugs Women’s Health Business Team, stated that empowered by Fangzhou Pharmaceutical’s digital capabilities, Bayer has delivered enhanced product and service experiences to patients through an “online + offline” model, achieving a revitalized upgrade of its business.

Fan Wendi, Vice President of Kelun Pharmaceutical and General Manager of its Marketing Center, stated that Fangzhou Pharmaceutical has consistently been Kelun Pharmaceutical’s most trusted partner in their digital collaboration. Moving forward, the strategic cooperation between the two parties will be further upgraded and expanded into broader areas.

Yin Jinqun, Director and Vice President of Chengdu Kanghong Pharmaceutical Group, stated that the two parties share a solid foundation for cooperation and look forward to deeper exchanges and collaboration in areas such as the integrated development of healthcare and digital brand marketing.

Digital transformation and upgrading are inevitably the trend of the future. Fangzhou Pharmaceutical’s digital chronic disease management services and customized marketing solutions have set a benchmark for digital upgrades in the industry. We look forward to more responsible and accountable leading healthcare enterprises leveraging digital empowerment to achieve dual improvements in products and services, jointly advancing the global process of healthcare digitalization.